[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Travere Therapeutics Inc (TVTX)

Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,162,366
  • Shares Outstanding, K 92,993
  • Annual Sales, $ 490,730 K
  • Annual Income, $ -25,550 K
  • EBIT $ -63 M
  • EBITDA $ -5 M
  • 60-Month Beta 1.13
  • Price/Sales 8.49
  • Price/Cash Flow 123.71
  • Price/Book 41.92

Options Overview Details

View History
  • Implied Volatility 42.21% (-0.61%)
  • Historical Volatility 104.31%
  • IV Percentile 1%
  • IV Rank 1.12%
  • IV High 220.62% on 03/19/26
  • IV Low 40.19% on 05/05/26
  • Expected Move (DTE 8) 2.47 (5.78%)
  • Put/Call Vol Ratio 0.98
  • Today's Volume 446
  • Volume Avg (30-Day) 5,276
  • Put/Call OI Ratio 1.33
  • Today's Open Interest 35,977
  • Open Int (30-Day) 52,326
  • Expected Range 40.20 to 45.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.20
  • Number of Estimates 6
  • High Estimate $0.03
  • Low Estimate $-0.51
  • Prior Year $-0.14
  • Growth Rate Est. (year over year) -42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.29 +50.80%
on 04/10/26
48.61 -12.24%
on 05/05/26
+10.99 (+34.70%)
since 04/07/26
3-Month
26.15 +63.14%
on 03/20/26
48.61 -12.24%
on 05/05/26
+12.95 (+43.59%)
since 02/06/26
52-Week
13.88 +207.35%
on 06/18/25
48.61 -12.24%
on 05/05/26
+22.43 (+110.87%)
since 05/07/25

Most Recent Stories

More News
Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Health...

TVTX : 42.66 (-4.69%)
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”)....

TVTX : 42.66 (-4.69%)
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 (the...

TVTX : 42.66 (-4.69%)
Travere: Q1 Earnings Snapshot

Travere: Q1 Earnings Snapshot

TVTX : 42.66 (-4.69%)
Travere Therapeutics Reports First Quarter 2026 Financial Results

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over year to $105 million FDA approval in FSGS expands...

TVTX : 42.66 (-4.69%)
Travere's FSGS Approval Afterglow Meets First Commercial Reality Check

Barchart Research What to Expect from TVTX Earnings TVTX Generated May 1, 2026 Current Price $44.12 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 4.87% Travere's FSGS Approval Afterglow...

TVTX : 42.66 (-4.69%)
Travere's FSGS Approval Afterglow Meets First Commercial Reality Check

Barchart Research What to Expect from TVTX Earnings TVTX Generated May 1, 2026 Current Price $44.12 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 4.87% Travere's FSGS Approval Afterglow...

TVTX : 42.66 (-4.69%)
Travere's FSGS Approval Afterglow Meets First Commercial Reality Check

Barchart Research What to Expect from TVTX Earnings TVTX Generated May 1, 2026 Current Price $44.12 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 4.87% Travere's FSGS Approval Afterglow...

TVTX : 42.66 (-4.69%)
Travere Therapeutics to Report First Quarter 2026 Financial Results

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will host...

TVTX : 42.66 (-4.69%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on April 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting...

TVTX : 42.66 (-4.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 48.82
2nd Resistance Point 47.39
1st Resistance Point 45.03
Last Price 42.66
1st Support Level 41.23
2nd Support Level 39.81
3rd Support Level 37.44

See More

52-Week High 48.61
Last Price 42.66
Fibonacci 61.8% 35.34
Fibonacci 50% 31.25
Fibonacci 38.2% 27.15
52-Week Low 13.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.